Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EXCEL Sub-Study: The Site of the Left Main Coronary Artery Lesion Does Not Alter History

The EXCEL study, originally presented at TCT 2016 and published simultaneously in the New England Journal of Medicine (NEJM), showed that angioplasty and surgery in patients with left main coronary artery disease have similar rates of mortality, infarction, and stroke at 3 years.

perforación coronaria en angioplastiaThis sub-study, recently published in J Am Coll Cardiol Intv, adds that the site of the left main coronary artery lesion (ostial, shaft, or bifurcation lesion) does not alter the outcomes of the overall study. An important detail: the EXCEL trial (unlike almost all studies carried out in these last years) did not include revascularization in its primary endpoint; only death, infarction, and stroke.

 

Revascularization was analyzed as a secondary endpoint and offered no surprises: clinically-driven revascularization was more frequent in patients with distal lesions, but it was similar to surgery in patients with ostial or shaft lesions.


Read also: Post-Dilation in Valve-in-Valve Implantation Offers Hemodynamic Improvement.


About 84.2% (n = 1559) of patients experienced distal bifurcation lesions vs. 15.8% (n = 293) who presented isolated ostial or shaft lesions.

 

At 3 years, there were no significant differences between angioplasty and surgery in the composite primary endpoint of death, infarction, and stroke regarding both the distal segment (15.6% vs. 14.9%; odds ratio [OR]: 1.08; 95% confidence interval [CI]: 0.81 to 1.42; p = 0.61) and isolated ostial or shaft lesions (12.4% vs. 13.5 %; OR: 0.90; 95% CI: 0.45 to 1.81; p = 0.77) (p for interaction = 0.65).


Read also: Noradrenaline seems superior to adrenaline in patients with cardiogenic shock.


Ischemia-driven revascularization was more frequent in patients who underwent angioplasty when the lesion was located in the distal segment of the left main coronary artery (13.0% vs. 7.2%; OR: 2.00; p = 0.0001), but there was no difference between both revascularization strategies in patients with ostial or shaft lesions (9.7% vs. 8.4%; OR: 1.18; p = 0.68).

 

Conclusion

In the EXCEL study, angioplasty and surgery were comparable in terms of death, infarction, or stroke at three years in patients with left main coronary artery lesions, including those with distal bifurcation lesions. Repeat revascularization during follow-up was more frequent after angioplasty in patients with distal lesions, but not in patients with shaft or ostial lesions.

 

Original title: Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site. Results from the EXCEL Trial.

Reference: Anthony H. Gershlick et al. J Am Coll Cardiol Intv 2018;11:1224-33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...